Amid equine influenza virus (EIV) season, a recent study has shown that the Fluvac Innovator from Zoetis is cross-reactive against three emerging World Organization for Animal Health (OIE) isolates.

The study demonstrated sera from horses vaccinated with the EIV vaccine were cross-reactive against:

  • Ayrshire 2013 (AY/13), European clade 2 isolate
  • Kentucky 2014 (KY/14), North American clade 1 isolate
  • Texas 2012 (TX/12), North American clade 1 isolate

The vaccinated horses demonstrated at least 97.4% cross-reactivity to these three recent EIV isolates. These high rates of seroconversion demonstrated that the vaccine is immunologically relevant against newly emerging North American clade 1 and European clade 2 EIV strains.

“These are the most recent OIE isolates that we have on file at the OIE reference lab at the University of Kentucky,” said Robert Holland, DVM, PhD, director of Zoetis outcomes research. “In result, there were good cross-reactive antibodies when vaccinated with Kentucky/97 Fluvac Innovator against those strains

Create a free account with TheHorse.com to view this content.

TheHorse.com is home to thousands of free articles about horse health care. In order to access some of our exclusive free content, you must be signed into TheHorse.com.

Start your free account today!

Already have an account?
and continue reading.